WHAT IS CLAIMED IS:

1. Use of a pharmaceutical composition in the manufacture of a medicament for preventing, treating or relieving a bone disease, wherein the pharmaceutical composition comprises at least one of *Lactobacillus plantarum* GKM3 and *Lactobacillus paracasei* GKS6, the *Lactobacillus plantarum* GKM3 was deposited in China General Microbiological Culture Collection Center (CGMCC) with a deposition number of CGMCC 14565 on August 25, 2017, and the *Lactobacillus paracasei* GKS6 was deposited in CGMCC with a deposition number of CGMCC 14566 on August 25, 2017.
2. The use as claimed in Claim 1, wherein the bone disease is an osteoporosis, a bone defect, a bone fracture, or a combination thereof.
3. The use as claimed in Claim 1, wherein the pharmaceutical composition is for use in the treatment of the bone disease of a subject, and the subject is subject to a once-daily administration, a multiple-daily administration, or a weekly administration.
4. The use as claimed in Claim 3, wherein the subject is a menopausal woman.
5. The use as claimed in Claim 1, wherein the pharmaceutical composition further includes a pharmaceutically acceptable carrier.
6. The use as claimed in Claim 1, wherein the medicament is in a dosage form suitable for oral administration.
7. The use as claimed in Claim 6, wherein the dosage form is selected from solutions, suspensions, emulsions, powders, tablets, pills, syrups, lozenges, troches, chewing gums, slurries, or capsules.
8. The use as claimed in Claim 1, wherein the bone disease is identified by a

bone parameter being a blood calcium concentration, a bone volume density (BV/TV), a trabecular number (Tb.N), a trabecular thickness (Tb.Th), a trabecular spacing (Tb.Sp), or a combination thereof, and the medicament improves the bone parameter.

9. The use as claimed in Claim 1, wherein the medicament reduces one of a pathological effect and a symptom of the bone disease.

10. The use as claimed in Claim 9, wherein the one of the pathological effect and the symptom of the bone disease is at least one of a bone fracture and a decreased blood calcium concentration.

11. Use of a pharmaceutical composition in the manufacture of a medicament for treating a calcium deficiency in blood to prevent, treat or relieve a bone disease, wherein the pharmaceutical composition comprises at least one of *Lactobacillus plantarum* GKM3 and *Lactobacillus paracasei* GKS6, the *Lactobacillus plantarum* GKM3 was deposited in China General Microbiological Culture Collection Center (CGMCC) with a deposition number of CGMCC 14565 on August 25, 2017, and the *Lactobacillus paracasei* GKS6 was deposited in CGMCC with a deposition number of CGMCC 14566 on August 25, 2017.

12. The use as claimed in Claim 11, wherein the pharmaceutical composition further includes a pharmaceutically acceptable additive.

13. The use as claimed in Claim 11, wherein the pharmaceutical composition further includes a pharmaceutically acceptable carrier.

14. The use as claimed in Claim 11, wherein the calcium deficiency is caused by a decreased estrogen level in a menopausal women.

15. The use as claimed in Claim 11, wherein the bone disease includes a bone parameter being a bone volume density (BV/TV), a trabecular number

(Tb.N), a trabecular thickness (Tb.Th), a trabecular spacing (Tb.Sp), or a combination thereof, and the medicament improves the bone parameter.

16. The use as claimed in Claim 11, wherein the bone disease is an osteoporosis, a bone defect, a bone fracture, or a combination thereof.
17. The use as claimed in Claim 11, wherein the medicament is in a dosage form suitable for oral administration.